Navigation Links
Mylan Confirms First-to-File Patent Challenge Relating to Lescol(R)
Date:10/22/2008

PITTSBURGH, Oct. 22 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) today confirmed that the company and its subsidiary, Mylan Pharmaceuticals Inc., have been sued by Novartis in connection with Fluvastatin Capsules USP, 20 mg (base) and 40 mg (base), the generic version of Novartis' Lescol(R) Capsules.

Mylan believes it is the first company to file a substantially complete Abbreviated New Drug Application (ANDA) containing a Paragraph IV certification for the product. The company filed an ANDA with the U.S. Food and Drug Administration (FDA) in June. Novartis filed a lawsuit Oct. 10 in the U.S. District Court for the District of New Jersey alleging infringement of U.S. Patent No. 5,354,772.

Fluvastatin Capsules, used in the treatment of high cholesterol, had approximately $60 million in sales for the twelve months ending June 30, 2008, according to IMS Health.

Currently, Mylan has 108 ANDAs pending FDA approval, 22 of which are potential first-to-file opportunities.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest -- and highest quality -- product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's second largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit http://www.mylan.com.

This press release includes statements that constitute "forward-looking statements," including with regard to the expected first to
'/>"/>

SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Mylan Launches First Generic Version of Antihypertensive Sular(R) ER in the United States
2. Mylan Announces Final FDA Approval for Ropinirole Hydrochloride Tablets
3. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
4. Mylan Announces Final FDA Approval for Balsalazide Disodium Capsules
5. Mylan Announces Tentative FDA Approval for Lamotrigine Tablets
6. Mylan Announces Appointment of Steven G. Zylstra as Vice President of Global Corporate Communication and Public Relations
7. Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD
8. Mylan to Host Investor Day on October 3, 2007
9. Mylan Announces Pricing of Tender Offers for its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015
10. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
11. Barr Confirms Patent Challenge of Sensipar(R) Tablets, 30mg, 60mg and 90mg
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... , - ... the Ability of,Cardiopoietic Cells to Restore Cardiac Function ... leading Belgian biotechnology company specialising,in cell-based therapies for ... has completed, two months ahead of schedule,enrolment in ... trial of C-Cure, a,unique stem cell therapy for ...
(Date:12/14/2009)... and THOUSAND OAKS, Calif., Dec. 14 ... Amgen Inc.(Nasdaq: AMGN ) today announced that ... worldwide rights to Array,s small-molecule glucokinase activator program, ... 1 clinical trial in patients with Type 2 ... the agreement, Array will receive an upfront payment ...
(Date:12/14/2009)... Dyadic International, Inc. (Pink Sheets: DYAI) ... collaboration with The Scripps Research Institute ("Scripps") by ... the genome of Dyadic,s patented and proprietary C1 ... of the successful relationship between the two organizations ... Scripps to annotate the C1 genome for the ...
(Date:12/14/2009)... N.J., Dec. 14 The third edition ... , published by the Infusion ... treatment for anthracycline extravasation.(1) Anthracyclines are a ... and epirubicin that have been used in the ... early 1970s.(2) ,, According to the ...
Breaking Biology Technology:Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure 2Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure 3Array BioPharma and Amgen Partner in Type 2 Diabetes 2Array BioPharma and Amgen Partner in Type 2 Diabetes 3Array BioPharma and Amgen Partner in Type 2 Diabetes 4Array BioPharma and Amgen Partner in Type 2 Diabetes 5Array BioPharma and Amgen Partner in Type 2 Diabetes 6Array BioPharma and Amgen Partner in Type 2 Diabetes 7Dyadic International Extends Collaboration With The Scripps Research Institute 2Dyadic International Extends Collaboration With The Scripps Research Institute 3Dyadic International Extends Collaboration With The Scripps Research Institute 4Dyadic International Extends Collaboration With The Scripps Research Institute 5Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 2Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 3Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 4Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 5
... (Nasdaq: KOOL ), a leading supplier of innovative ... for treatment of disease,and injury, today reported results for ... Revenues for the quarter ended December 31, 2007, ... for the second quarter of,fiscal 2007 and $3.6 million ...
... YORK, Feb. 6 Immtech Pharmaceuticals,Inc. (Amex: IMM ... February,11, 2008, at 4.30 PM (ET) to discuss its ... to present an update on the Company,s,scientific and clinical ... to join the call by dialing (888) 338-8374 and ...
... Risk of Heart ... Disease and Diabetes, BIRMINGHAM, ... the largest private,insurers in Arizona as well as Medicare, Medicaid and ... Auto Profile),Test, the most comprehensive cholesterol test available. That means almost,90 ...
Other Biology Technology:ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year Over Year 2ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year Over Year 3ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year Over Year 4ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year Over Year 5ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year Over Year 6ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year Over Year 7ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year Over Year 8Immtech Investor Conference Call Scheduled for February 11, 2008 2VAP Cholesterol Test From Atherotech Covers 90 Percent of Arizona Insured 2
(Date:12/14/2009)... Society (BMES) have founded a new journal Cardiovascular ... CVET is a forum for research on all ... first issue of the new quarterly journal will appear ... at Springer, Annals of Biomedical Engineering and ... Engineering and Technology will present a wide spectrum ...
(Date:12/14/2009)... Nations Framework Convention on Climate Change taking place ... ,Bend the Trend, event on Sunday evening to ... the screening of the new ,Environmental Atlas of ... joint project of the European Environment Agency (EEA), ... a series of short films showing the significance ...
(Date:12/13/2009)... Conn.A team led by Yale University researchers has ... blood for the first time. Their findings, which ... of Nature Nanotechnology , could dramatically simplify ... and other diseases. , The teamled ... Engineering & Applied Science, and Tarek Fahmy, an ...
Breaking Biology News(10 mins):Biomedical Engineering Society's new journal to be published by Springer 2'Environmental Atlas of Europe' unveiled at COP15 2Scientists use nanosensors for first time to measure cancer biomarkers in blood 2The worlds most common operation 60981 1Antarctica glacier retreat creates new carbon dioxide store 10666 1Antarctica glacier retreat creates new carbon dioxide store 10666 2Charles Darwin and modern biology 10661 1
... to the largest body of ice on Earth. Prior to ... exist beneath the Antarctic ice sheets, which can be more ... to be too extreme. However, Brent Christner, assistant professor of ... time in one of the worlds most hostile environments conducting ...
... forest cover in El Salvador in the September issue ... land policy changes, and monies sent to family members ... The study, by Susanna B. Hecht and Sassan S. ... to document substantial increases in the area of El ...
... at Chicago researchers have identified new sites on ... be delivered to treat infections. , "The primary ... caused by the pathogens which became resistant to ... of UIC,s Center for Pharmaceutical Biotechnology and lead ...
Other Biology News:LSU professor looks for life in and under antarctic ice 2LSU professor looks for life in and under antarctic ice 3Population movements and money remittances spur forest regrowth 2UIC researchers find promising new targets for antibiotics 2
... The CopyControl™ vector can be induced ... These vectors provide the stability of single-copy ... cosmids or other cloning vectors. The kits ... (ligation reagents, insert size screening system) necessary ...
... 3T3 cells were cultured in DMEM with 4 ... of growth. In order to keep the ... in acetone-methanol. The cells are arrayed on ... each wells surface specifically treated to enhance cellular ...
... vector can be induced prior to DNA ... the stability of single-copy BACs with the ... cloning vectors. The kits provide the linearized ... size screening system) necessary to create a ...
...
Biology Products: